(Q36395728)

13 August 2017

2 references

28 September 2019

20 November 2019

Clinical uses of botulinum neurotoxins: current indications, limitations and future developments (English)

1 reference

13 August 2017

1 reference

28 September 2019

1 reference

20 November 2019

Sheng Chen

1

1 reference

13 August 2017

19 October 2012

1 reference

PMCID

3496996

13 August 2017

1 October 2012

2 references

28 September 2019

20 November 2019

3 references

13 August 2017

28 September 2019

20 November 2019

4

1 reference

13 August 2017

10

1 reference

13 August 2017

913-939

1 reference

Creative Commons Attribution 3.0 Unported

13 August 2017

2 references

28 September 2019

Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins

20 November 2019

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin for the treatment of strabismus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Towards new uses of botulinum toxin as a novel therapeutic tool

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin type A for upper limb spasticity after stroke

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Engineering botulinum neurotoxin to extend therapeutic intervention.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Glycosylated SV2 and Gangliosides as Dual Receptors for Botulinum Neurotoxin Serotype F

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Cell entry strategy of clostridial neurotoxins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin for the treatment of strabismus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Receptor and substrate interactions of clostridial neurotoxins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Engineered toxins: new therapeutics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Translocation of botulinum neurotoxin light chain protease by the heavy chain protein-conducting channel

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin in spasticity treatment in adults.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Treatment of juvenile spasticity with botulinum toxin type A.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

New therapeutic approaches to diabetic gastroparesis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

The use of botulinum toxin for spasticity after spinal cord injury.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Evidence based medicine in the use of botulinum toxin for back pain

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin in the treatment of strabismus. A review of its use and effects

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

The treatment of cervical dystonia with botulinum toxins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Regulated airway goblet cell mucin secretion.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Treatment of chronic low back pain with botulinum neurotoxins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Physiology of airway mucus secretion and pathophysiology of hypersecretion.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Evidence for the effectiveness of botulinum toxin for spasmodic dysphonia from high-quality research designs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin: from life-threatening disease to novel medical therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

SNAREs--engines for membrane fusion

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin for gastrointestinal disorders: therapy and mechanisms

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Epithelial sodium channel is regulated by SNAP-23/syntaxin 1A interplay

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

SV2 is the protein receptor for botulinum neurotoxin A.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin treatment of adult spasticity : a benefit-risk assessment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Unlabeled uses of botulinum toxins: a review, part 2.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Structure and function of SNARE and SNARE-interacting proteins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Identification of soluble N-ethylmaleimide-sensitive factor attachment protein receptor exocytotic machinery in human plasma cells: SNAP-23 is essential for antibody secretion.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

A new wrinkle on pain relief: re-engineering clostridial neurotoxins for analgesics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin type A therapy for hemifacial spasm

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin type A versus botulinum toxin type B for cervical dystonia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin type A therapy for cervical dystonia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin and wrinkles: few side effects and effective combining procedures with other treatments

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin in clinical practice

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Treatment of cervical dystonia with botulinum toxin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Basic immunological aspects of botulinum toxin therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Is the light chain subcellular localization an important factor in botulinum toxin duration of action?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Plasma membrane localization signals in the light chain of botulinum neurotoxin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Use of botulinum toxin type A and type B for spasticity in upper and lower limbs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Emerging therapeutic applications of botulinum toxin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

A focused review on the use of botulinum toxins for neuropathic pain

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

A focused review of the use of botulinum toxins for low back pain

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

The t-SNARE syntaxin 4 is regulated during macrophage activation to function in membrane traffic and cytokine secretion.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Function of the t-SNARE SNAP-23 and secretory carrier membrane proteins (SCAMPs) in exocytosis in mast cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Gastrointestinal uses of botulinum toxin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin type B: a new injectable treatment for cervical dystonia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin A and chronic low back pain: a randomized, double-blind study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Involvement of SNAP-23 and syntaxin 6 in human neutrophil exocytosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

The current use of botulinum toxin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Soluble NSF attachment protein receptors (SNAREs) in RBL-2H3 mast cells: functional role of syntaxin 4 in exocytosis and identification of a vesicle-associated membrane protein 8-containing secretory compartment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Use of botulinum toxin A in the treatment of hemifacial spasm and blepharospasm

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Proteolysis of SNAP-25 by types E and A botulinal neurotoxins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Use of botulinum toxin in the treatment of cervical dystonia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Cervical dystonia: a review the role of botulinum toxin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Mechanism of action of tetanus and botulinum neurotoxins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin injection of eye muscles to correct strabismus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Pharmacologic weakening of extraocular muscles.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Drooling and its management in cerebral palsy.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum toxin injections for cervical dystonia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Insights into the different catalytic activities of Clostridium neurotoxins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Mechanism of substrate recognition by botulinum neurotoxin serotype A.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Quantification of SNARE protein levels in 3T3-L1 adipocytes: implications for insulin-stimulated glucose transport

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Clinical spectrum of botulism.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Gangliosides mediate inhibitory effects of tetanus and botulinum A neurotoxins on exocytosis in chromaffin cells

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus.

28 June 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Mode of action of botulinum neurotoxin: pathological, cellular and molecular aspect

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Analysis of active site residues of botulinum neurotoxin E by mutational, functional, and structural studies: Glu335Gln is an apoenzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Substrate recognition strategy for botulinum neurotoxin serotype A.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Commentary: Botulinum toxin in clinical medicine: part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Use of botulinum toxin in the treatment of chronic myofascial pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Botulinum toxin type A and B for the reduction of hypersalivation in children with neurological disorders: a focus on effectiveness and therapy adherence.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Botulinum neurotoxin type A injections for vaginismus secondary to vulvar vestibulitis syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Different treatment modalities for refractory vaginismus in western Saudi Arabia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Improvement of wound healing after hemorrhoidectomy: a double-blind, randomized study of botulinum toxin injection

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Use of botulinum toxin type A to prevent widening of facial scars.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Effects of botulinum toxin type a on collagen deposition in hypertrophic scars.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

The effect on quality of life of long-term botulinum toxin A injections to maintain ocular alignment in adult patients with strabismus.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

What stands in the way of treating palmar hyperhidrosis as effectively as axillary hyperhidrosis with botulinum toxin type A.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496996

Treatment of Chronic Low Back Pain With Successive Injections of Botulinum Toxin A Over 6 Months

21 September 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FTOXINS4100913

Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions

21 January 2018

1 reference

12 December 2020

Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences

1 reference

12 December 2020

Botulinum toxin A--injection for cervical dystonia

1 reference

12 December 2020

OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial

1 reference

12 December 2020

[Treatment of hemifacial spasm with botulinum A toxin]

1 reference

12 December 2020

Botulinum toxin in cervical dystonia

1 reference

12 December 2020

The translocation of botulinum A neurotoxin by chromaffin cells is promoted in low ionic strength solution and is insensitive to trypsin

1 reference

12 December 2020

Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A

1 reference

12 December 2020

Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery

1 reference

12 December 2020

Neurotoxins licensed as treatment for neck neuromuscular disorder

1 reference

12 December 2020

Botulinum toxin use in pediatric esophageal achalasia: a case report

1 reference

12 December 2020

Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design

1 reference

12 December 2020

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia

1 reference

12 December 2020

Gastrointestinal uses of botulinum toxin

1 reference

12 December 2020

[Botulinum toxin: a new dimension for spasticity]

1 reference

12 December 2020

Hemifacial spasm and its treatment with botulinum toxin

1 reference

12 December 2020

Different response of the knockout mice lacking b-series gangliosides against botulinum and tetanus toxins

1 reference

12 December 2020

Molecular mechanisms of platelet exocytosis: role of SNAP-23 and syntaxin 2 in dense core granule release

1 reference

12 December 2020

OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program

1 reference

12 December 2020

Botulinum toxin-A to improve urethral wound healing: an experimental study in a rat model

1 reference

12 December 2020

[Botulinum toxin A in the treatment of anal fissure]

1 reference

12 December 2020

OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

1 reference

12 December 2020

Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial

1 reference

12 December 2020

Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study

1 reference

12 December 2020

A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro

1 reference

12 December 2020

[Effect of botulinum toxin type A on the expression of substance P, calcitonin gene-related peptide, transforming growth factor beta-1 and alpha smooth muscle actin A in wound healing in rats]

1 reference

12 December 2020

Botulinum toxin treatment for oropharyngeal dysphagia associated with diabetic neuropathy

1 reference

12 December 2020

Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugates

1 reference

12 December 2020

[Successful treatment of diabetic gustatory hyperhidrosis with topical glycopyrrolate]

1 reference

12 December 2020

Botulinum toxin therapy for cervical dystonia

1 reference

12 December 2020

Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response

1 reference

12 December 2020

SNAP-23 Is Not Cleaved by Botulinum Neurotoxin E and Can Replace SNAP-25 in the Process of Insulin Secretion

1 reference

12 December 2020

[Botulinum toxin injections for the treatment of strabismus. Which indications are still useful today?]

1 reference

12 December 2020

Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia

1 reference

12 December 2020

[Efficacy and safety of botulinum toxin in the treatment of sialorrhea in children with neurological disorders]

1 reference

12 December 2020

Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections

1 reference

12 December 2020

Botulinum toxin for spastic gastrointestinal disorders

1 reference

12 December 2020

The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings

1 reference

12 December 2020

Identifiers

DOI

10.3390/TOXINS4100913

1 reference

13 August 2017

1 reference

13 August 2017

1 reference

PMCID

3496996